Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zevra Therapeutics's EBIT per Share for the
three
months ended in Jun. 2026 was €0.18.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €1.08.
During the past 3 years, the average EBIT per Share Growth Rate was 53.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Zevra Therapeutics's EBIT per Share or its related term are showing as below:
STU:1GDA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -57.6 Med: 17.25 Max: 67.9
Current: 53.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Zevra Therapeutics was 67.90% per year. The lowest was -57.60% per year. And the median was 17.25% per year.
STU:1GDA's 3-Year EBIT Growth Rate is ranked better than 88.87% of 1168
companies
in the Biotechnology industry
Industry Median: 15.45
vs STU:1GDA: 53.20
Zevra Therapeutics (STU:1GDA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Zevra Therapeutics EBIT per Share Related Terms
Zevra Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Zevra Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zevra Therapeutics (STU:1GDA) has a EBIT per Share of €1.08 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Zevra Therapeutics and its competitors. According to the industry distribution chart, Zevra Therapeutics ranks #130 out of 1168 companies in the Biotechnology industry, placing it in the top 11.1%.
Is Zevra Therapeutics' EBIT per Share too high?
Zevra Therapeutics' current EBIT per Share is €1.08. Based on the distribution chart, Zevra Therapeutics ranks #130 out of 1168 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zevra Therapeutics has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zevra Therapeutics' EBIT per Share compare to TECX and RLMD?
According to the Biotechnology industry distribution chart, Zevra Therapeutics ranks #130 out of 1168 companies for EBIT per Share. This places Zevra Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.45, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Zevra Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zevra Therapeutics's current EBIT per Share is €1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zevra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zevra Therapeutics (STU:1GDA) is currently considered Possible Value Trap. The stock's GF Value™ is €17.92, compared to a current price of €9.80 — trading 45.3% below its estimated fair value. The current EBIT per Share is €1.08. Zevra Therapeutics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Zevra Therapeutics (STU:1GDA), the current EBIT per Share is €1.08 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zevra Therapeutics (STU:1GDA) Overvalued in 2026?
Based on GuruFocus' analysis, Zevra Therapeutics stock appears to be undervalued.
The current stock price of €9.80 is trading 45.3% below its estimated GF Value™ of €17.92.
GuruFocus considers Zevra Therapeutics to be Possible Value Trap.
Key valuation signals for STU:1GDA:
EBIT per Share: €1.08
GF Value™: €17.92 vs. price of €9.80 (45.3% below fair value)
No single metric tells the full story. See the STU:1GDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
69GF Score
Get the complete analysis for STU:1GDA
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1GDA has been successfully added to your 
